Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical ...
Greenwich LifeSciences Provides Update on Commercial Manufacturing
STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical ...
Greenwich LifeSciences announces activation of Phase 3 trial in Poland
Greenwich LifeSciences (GLSI) announced the activation of clinical sites in Poland in tis Phase III clinical trial, FLAMINGO-01, which is ...
Greenwich LifeSciences gains after GP2 commercial manufacturing update
Greenwich LifeSciences (GLSI) stock gained after the company updated on commercial manufacturing of its lead candidate GP2.
Nasdaq6d
Greenwich LifeSciences, Inc. Updates on GP2 Commercial Manufacturing and Phase III Clinical Trial Progress
Greenwich LifeSciences updates on commercial manufacturing of GP2 and prepares for BLA filing for GLSI-100 in breast cancer treatment. Greenwich LifeSciences, Inc. announced progress in the ...
Greenwich LifeSciences provides update on commercial manufacturing of GP2
Greenwich LifeSciences (GLSI) provided an update on the commercial manufacturing of GP2. In addition to the submission of the Phase III ...
Morningstar6d
Greenwich LifeSciences Provides Update on Commercial Manufacturing
STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial ...
Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Commercial Manufacturing
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...